Chembio Diagnostics Inc. [CEMI] shares are down more than -10.99% this year and recently decreased -0.02% or -$0.08 to settle at $4.86. Analysts expect CEMI to grow earnings at a 25.00% annual rate over the next 5 years. CEMI has a short ratio of 0.95. This implies that the market is currently less bearish on the outlook for CEMI.

On 2, October 2020, Chembio Diagnostics Receives FDA Approval for DPP HIV-Syphilis System. According to news published on Yahoo Finance, First Rapid Test Approved in U.S. to Aid in Diagnosis of Both HIV and Syphilis from Single Patient Sample.

Analyst Birdseye View:

The most recent analyst activity for Chembio Diagnostics Inc. [NASDAQ:CEMI] stock was on June 17, 2020, when it was Downgrade with a Hold rating from Craig Hallum. On June 17, 2020, Canaccord Genuity Downgrade a Hold rating and boosted its price target on this stock to $7. On May 26, 2020, Robert W. Baird Initiated an Outperform rating and increased its price target to $21. On March 04, 2020, The Benchmark Company Reiterated a Speculative buy rating and decreased its price target to $6. On March 04, 2020, The Benchmark Company Reiterated a Speculative buy rating and boosted its amount target on this stock to $5. On December 19, 2018, Dougherty & Company Initiated a Buy rating. On August 11, 2016, The Benchmark Company Reiterated a Speculative buy rating and amplified its amount target to $9.

In the past 52 weeks of trading, this stock has oscillated between a low of $2.25 and a peak of $15.89. Right now, according to Wall Street analyst the average 12-month amount target is $5.00. At the most recent market close, shares of Chembio Diagnostics Inc. [NASDAQ:CEMI] were valued at $4.86. According to the average price forecast, investors can expect a potential return of 0.0%.


Chembio Diagnostics Inc. [NASDAQ:CEMI] most recently reported quarterly sales of 5.11 billion, which represented growth of -48.50%. This publicly-traded organization’s revenue is $106,370 per employee, while its income is -$42,207 per employee. This company’s Gross Margin is currently 26.50%, its Operating Margin is -65.00%, its Pretax Margin is -41.13, and its Net Margin is -39.68. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -24.65, -47.68, -30.26 and -33.22 respectively.

The Principal structure of this organization shows its whole liability to whole principal at 51.55 and the whole liability to whole assets at 36.51. It shows enduring liability to the whole principal at 49.96 and enduring liability to assets at 0.35 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 4.87 points at 1st support level, the second support level is making up to 4.79. But as of 1st resistance point, this stock is sitting at 5.06 and at 5.17 for 2nd resistance point.

Chembio Diagnostics Inc. [CEMI] reported its earnings at -$0.42 per share in the fiscal quarter closing of 6/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.39/share signifying the difference of -0.03 and -7.70% surprise value. Comparing the previous quarter ending of 3/30/2020, the stated earnings were -$0.29 calling estimates for -$0.23/share with the difference of -0.06 depicting the surprise of -26.10%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Chembio Diagnostics Inc. [NASDAQ:CEMI] is 3.80. Likewise, the Quick ratio is also the same, showing Cash ratio at 2.84. Now if looking for a valuation of this stock’s amount to sales ratio it’s 2.24 and it’s amount to book ratio is 3.36.

Insider Stories

The most recent insider trade was by Potthoff John Gary, Director, and it was the purchase of 10000.0 shares on Nov 11.